Business Description
Q32 Bio is a Waltham, Massachusetts-based biotechnology company focused on treating autoimmune and inflammatory conditions by targeting the underlying causes of immune system dysfunction. Its lead drug candidate, Bempikibart, has completed mid-stage clinical trials for two skin conditions ? atopic dermatitis and hair loss caused by alopecia areata ? and works by blocking specific immune signals that drive these diseases. The company is also working on a separate therapy, ADX-096, aimed at eye conditions, along with a broader pipeline of treatments designed to suppress harmful immune activity in targeted tissues. Founded in 2017, Q32 Bio is still in the clinical stage, meaning its treatments have not yet received regulatory approval.
